Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study

BACKGROUND: In the prepertuzumab era, we evaluated the clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who underwent first-line trastuzumab-based or lapatinib-based therapy according to prior exposure to (neo)adjuvant trastuzumab....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Blondeaux, Eva, Ferreira, Arlindo R, Poggio, Francesca, Puglisi, Fabio, Bighin, Claudia, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Lai, Antonella, Sini, Valentina, Minuti, Gabriele, Mura, Silvia, Fontana, Andrea, Fregatti, Piero, Cardinali, Barbara, Lambertini, Matteo, Del Mastro, Lucia
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7437709/
https://ncbi.nlm.nih.gov/pubmed/32817059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000719
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados